1-3 of 3
Emma Link, PhD
Close
Sort by
Journal Articles

Plerixafor Plus Single-Dose Pegfilgrastim for Hematopoietic Stem and Progenitor Cell Mobilization: An Efficient and Safe Regimen In Good and Poor Mobilizer Patients

Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Lisa Demosthenous, Glen Wiesner, PhD, Emma Link, PhD, David Alan Westerman, MBBS, FRACP, FRCPA, Neil Came, MBBS, FRACP, FRCPA, John F Seymour, MD, FRACP, PhD, Miles Prince, MD, FRACP, FRCPA
Journal: Blood
Blood (2010) 116 (21): 2256.
https://doi.org/10.1182/blood.V116.21.2256.2256
Published: 2010
Journal Articles

Cardiac Safety of One Versus Four Hour Romidepsin (Istodax®) Infusion In the Setting of a Phase I/II Trial of Romidepsin, Dexamethasone and Bortezomib for Relapsed or Refractory Multiple Myeloma

Sam A Ruell, RN, Miles Prince, MD, FRACP, FRCPA, Hang Quach, MBBS, FRACP, FRCPA, MD, Emma Link, PhD, Joanne Dean, Simon J. Harrison, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 5037.
https://doi.org/10.1182/blood.V116.21.5037.5037
Published: 2010
Journal Articles

TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy

David Alan Westerman, MBBS, FRACP, FRCPA, Giada Zapparoli, Chelsee Hewitt, Kevin Lynch, MBBS, Linda Mileshkin, Emma Link, PhD, Alexander Dobrovic, H. Miles Prince
Journal: Blood
Blood (2010) 116 (21): 4046.
https://doi.org/10.1182/blood.V116.21.4046.4046
Published: 2010